Introduction
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, essential for hundreds of metabolic reactions including energy production, DNA repair, and gene expression regulation. NAD+ levels decline significantly with age -- a decline increasingly recognized as a hallmark of aging. NAD+ precursor supplementation, particularly with nicotinamide mononucleotide (NMN), has emerged as a major focus of anti-aging research. This article reviews the current evidence from both preclinical and clinical studies.
Age-Related NAD+ Decline
NAD+ concentration decreases in multiple tissues with age, including skin, blood, liver, muscle, and brain. This decline is driven by both reduced synthesis and increased consumption by NAD+-consuming enzymes such as PARPs (poly-ADP-ribose polymerases) and CD38. The age-related decline in NAD+ is associated with mitochondrial dysfunction, genomic instability, and impaired cellular stress responses -- processes that underlie many age-related diseases.
Preclinical Evidence
The most influential preclinical study was published by Mills et al. (2016) in Cell Metabolism. This landmark study demonstrated that long-term NMN administration in mice effectively mitigated age-associated physiological decline without obvious toxicity. Specifically, NMN supplementation suppressed age-related body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profiles, and ameliorated eye function (PubMed: 28068222).
The comprehensive nature of these improvements across multiple organ systems suggested that NAD+ restoration addresses a fundamental mechanism of aging rather than targeting individual symptoms.
Human Clinical Trials
The transition from animal models to human studies has progressed through several clinical trials, though the evidence base remains limited. A comprehensive update published by Nadeeshani et al. (2024) in Advances in Nutrition reviewed the current clinical trial landscape, noting that NMN supplementation increases blood NAD+ concentrations safely with oral dosing up to 900 mg daily, with optimal clinical efficacy at 600 mg for both NAD+ levels and physical performance measures (PubMed: 37619764).
Multicenter Dose-Response Trial
The most rigorous trial to date was a randomized, multicenter, double-blind, placebo-controlled study conducted in Japan with 108 healthy middle-aged adults. Published by Yi et al. (2023) in GeroScience, the study demonstrated that NMN supplementation significantly increases blood NAD+ concentrations in a dose-dependent manner with good safety and tolerability (PubMed: 36482258).
Functional Outcomes in Older Adults
Igarashi et al. (2022) published in npj Aging a study on chronic NMN supplementation in healthy older men. The results showed significantly elevated blood NAD+ and NAD+ metabolite concentrations, with nominally significant improvements in gait speed and grip test performance -- key functional measures of aging (PubMed: 35927255).
Mechanisms of Action
NAD+ participates in cellular metabolism through several key mechanisms:
- Sirtuin Activation: NAD+ is a required substrate for sirtuins (SIRT1-7), which regulate gene expression, DNA repair, and metabolic pathways
- Mitochondrial Function: NAD+ is essential for the electron transport chain and oxidative phosphorylation
- DNA Repair: PARP enzymes consume NAD+ to repair DNA damage, and insufficient NAD+ impairs this repair capacity
- Epigenetic Regulation: NAD+-dependent enzymes modify chromatin structure, affecting gene expression patterns
Administration Routes
NMN has been studied primarily via oral supplementation in capsule form. Intravenous NAD+ infusion is offered in some clinical settings, delivering NAD+ directly to the bloodstream. Subcutaneous NAD+ peptide formulations also exist. The oral NMN route has the most clinical trial data supporting its bioavailability and safety.
Limitations of Current Evidence
While the preclinical evidence is compelling, human clinical data remain limited. Most trials have been small (8-66 participants in individual studies, with the largest being 108), short-term, and at phase 1 level. Long-term safety data in humans are not yet available. The dramatic anti-aging effects seen in mice have not been replicated to the same degree in humans, where the relationship between NAD+ supplementation and functional aging outcomes remains to be fully established.
Summary
NAD+ precursor supplementation, particularly NMN, represents one of the most scientifically grounded approaches to addressing age-related metabolic decline. Preclinical evidence demonstrates comprehensive benefits across multiple organ systems, and early human trials confirm that oral NMN safely increases blood NAD+ levels. However, large-scale, long-term clinical trials are needed to establish whether NAD+ restoration in humans can produce the functional anti-aging benefits observed in animal models.